Regulatory Effects and Mechanisms of m6A Methylation Modification in Cardiovascular Diseases
PU Rui1,2, CHEN Ziyang1,2, YUAN Lingyan2*
m6A (N6-methyladenine) is the most common internal chemical modification in eukaryotic mRNA. Studies have shown that M6A methylation plays an important role in the regulation of cardiovascular diseases such as heart failure, myocardial hypertrophy, atherosclerosis and ischemic cardiomyopathy, and has made great progress in the past three years. For example, m6A methyltransferase can delay heart failure and promote myocardial repair after heart failure, which provides a new perspective for the treatment of heart failure; various m6A methylation regulators can inhibit the process of atherosclerosis by regulating endothelial cell function, inflammatory response and cell cycle progression. In ischemic cardiomyopathy, m6A methyltransferase and demethylase lay a foundation for the treatment of ischemic cardiomyopathy through feedback regulation. In addition, recent studies have shown that epigenetic modification of mRNA has a great effect on cardiac hypertrophy. At the same time, researchers have made great progress in the study of the molecular mechanism of epigenetic modification in the regulation of cardiac hypertrophy. It has been found that m6A methylation can be used as a therapeutic target for maintaining cardiac function and homeostasis by regulating related signal pathways. In view of this, by reviewing the latest research progress at home and abroad in the past three years, this paper deeply discussed the regulatory role and molecular mechanism of m6A methylation in various cardiovascular diseases, in order to provide theoretical reference for the prevention and treatment of various cardiovascular diseases.
CN
EN